**Yes, Medline Industries (a major medical supplies manufacturer and distributor with multiple warehouses) has faced recent regulatory scrutiny, though not primarily tied to its warehouses themselves.** ### Key Recent Developments (2025–2026): - **FDA Warning Letters (2026)**: Medline received multiple FDA warnings for quality and manufacturing violations. One in March 2026 (for a New York facility) cited issues with angiographic control syringes, including failures in corrective actions, design controls, cleanrooms, and hundreds of complaints about disconnections that could cause safety risks like air embolisms. Another followed in May/June 2026 regarding microbial contamination (e.g., Bacillus cereus) in drug products at other sites, with inadequate investigations. - These triggered **securities fraud investigations** by law firms on behalf of shareholders, as the news caused a ~7% stock drop in early June 2026. - **Ongoing/Related Litigation**: Medline has a history of product liability (e.g., bed rails, ethylene oxide exposure lawsuits from sterilization facilities) and older labor/wage issues at distribution centers, but no major new warehouse-specific lawsuits stand out in the last year or so. - **Today’s Tracy, CA Warehouse Fire (June 11, 2026)**: A massive fire destroyed or heavily damaged Medline’s large distribution warehouse in Tracy. No injuries, all employees accounted for. The cause is under investigation, but there are no reports of it immediately leading to legal action or violations. Older issues include tax disputes over warehouse construction incentives, past OSHA fines for workplace safety, and resolved False Claims Act/kickback settlements. In summary, **recent legal/regulatory pressure centers on FDA manufacturing quality issues** (not directly warehouses), leading to investor probes. The Tracy fire is very recent and still under investigation with no confirmed legal fallout yet. For the latest, check FDA.gov or news sources, as situations can evolve quickly.